The Quantellect read.As of Nov 19, 2026, 7 active firms cover Vor Biopharma Inc: 6 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $27.00 to $50.00, a moderate spread. The average target of $38.00 sits 113% above the current $17.82. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.99 next quarter toward $-3.34 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy686%
Neutral114%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$38.00
+113.2% upside
Average target across 6 active firms as of Nov 19, 2026 vs $17.83 current
Highest Target$50.00
Average Target$38.00
Lowest Target$27.00
Detailed analyst forecasts for VOR
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 6 of 7 active firms rate VOR a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
VOR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.99
Range $-0.99 – $-0.99 · 1 analysts · +36% YoY
Next period, 1 analysts expect Vor Biopharma Inc to earn $-0.99 a share (range $-0.99 – $-0.99), versus $-0.73 a year earlier. Full-year consensus is $-6.67, growing to $-3.34 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Vor Biopharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VOR.
#1
David Nierengarten
Wedbush · Rank #24
Neutral
$0.40-97.8% to target
Overall win rate
48%
+ Follow
#2
Silvan Tuerkcan
JMP Securities · Rank #69
Neutral
$6.00-66.3% to target
Overall win rate
51%
+ Follow
#3
Anupam Rama
JP Morgan · Rank #171
Buy
$40.00+124.4% to target
Overall win rate
48%
+ Follow
#4
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$31.00+73.9% to target
Overall win rate
38%
+ Follow
#5
SW
Stephen Willey
Stifel · Rank #474
Buy
$40.00+124.4% to target
Overall win rate
29%
+ Follow
VOR stock forecast FAQ
What is VOR's average 12-month price target?+
The 6 active firms with a live target average $38.00 for Vor Biopharma Inc over the next 12 months, ranging from a $50.00 high to a $27.00 low, as of Nov 19, 2026.
Is VOR stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for VOR?+
The Street-high target is $50.00 (Jefferies), and the Street-low is $27.00 (Wedbush). The average of all 6 active-firm targets is $38.00.
How many active Wall Street firms cover VOR?+
7 active firms have a recognized rating on Vor Biopharma Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering VOR?+
Among analysts who currently cover VOR, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Neutral with a $0.40 target.
What is Vor Biopharma Inc's projected EPS for next quarter?+
The consensus estimate is $-0.99 per share (range $-0.99 – $-0.99) across 1 analysts. Full-year EPS is projected at $-6.67, rising to $-3.34 the following year.
How much revenue is Vor Biopharma Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading VOR lately?+
As of Nov 19, 2026, 6 of 7 active firms rate VOR a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VOR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.